

Excess Treatment Costs Guidance for York Teaching Hospitals NHS Foundation Trust

**IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE THAT
THE CORRECT VERSION IS BEING USED**

All staff should regularly check the R&D Unit's website and/or Q-Pulse for information relating to the implementation of new or revised versions. Staff must ensure that they are adequately trained in the new procedure and must make sure that all copies of superseded versions are promptly withdrawn from use unless notified otherwise by the SOP Controller.

The definitive versions of all R&D Unit SOPs appear online. If you are reading this in printed form check that the version number and date below is the most recent one as shown on the R&D Unit website: www.research.yorkhospitals.nhs.uk/sops-and-guidance/ and/or Q-Pulse

Template Reference:	R&D/G07
Version Number:	2.0
Author:	Lydia Harris
Implementation date of current version:	14 th February 2024

Approved by:	Name/Position:	Deborah Phillips, Research Advisor
	Date:	17 th January 2024
	Name/Position:	Sarah Sheath, SOP Controller
	Date:	17 th January 2024

This Template will normally be reviewed every 3 years unless changes to the legislation require otherwise

Version History Log

This area should detail the version history for this document. It should detail the key elements of the changes to the versions.

Version	Date Implemented	Reviewers	Details of significant changes
1.0	14 th August 2019		N/A
2.0	14 th February 2024	Lydia Harris	Complete re write to accompany national changes to ETC payments

UNCONTROLLED DOCUMENT WHEN PRINTED

Contents

	<u>Page No</u>
Version	2.0
1. Summary	1
2. Background	1
3. Our New ETC policy	2
4. Our processes	3
5. Conclusion	4

1. Summary

All Excess Treatment Costs will be covered by the R&D Department in a financial year up to the value of the Trusts ETC threshold (currently £4729) after which time ETCs will be covered by the Clinical Research Network.

Only R&D will therefore incur any ETC expenditure, Care Groups will never have to cover an Excess Treatment Cost.

2. Background

This Policy replaces the Excess Treatment Costs (ETC) Policy written in 2019, due to the national changes on how ETC's are distributed to NHS Trusts.

[NHS Accelerated Access Collaborative » Excess treatment costs \(england.nhs.uk\)](https://www.england.nhs.uk/accelerated-access-collaborative/excess-treatment-costs/)

ETCs are the difference between Treatment Costs and the costs of the existing standard treatment. For the past few years each Trust in England has been given a threshold to meet before they can apply for support for ETC payment. This was 0.01% of a Trust operating budget but has now been reduced to 0.001%. Our Trust's ETC threshold is currently therefore £4729, and so a new ETC policy is required.

3. Our New ETC policy April 2023

Going forward, when deciding to adopt a research study within the Trust the Research Delivery Facilitators will review the documents provided by the sponsor to review the identified ETCs. These will be contained in the SoECAT (Schedule of Events Cost Attribution Template), the Head of R&D will be informed of any identified ETCs for approval.

If approved, the study will proceed to open, and the R&D department will cover the costs of the ETC every financial year. This will be portrayed to the Care Group by the Research Delivery Facilitators, making it clear that the Care Group will incur no costs when the study opens.

Where studies have large amounts of ETCs in a financial year, the Research Delivery Facilitators will explain to Care Groups that R&D will cover the ETCs up to a value of the Trusts ETC threshold, in a financial year, after which time the Care Groups will receive the funds from the Clinical Research network (CRN). So, for all research studies the ETC's are not incurred by the Care Group.

R&D will, however, never be able to support ETCs that are not identified within the SoECAT, as they will not count towards the Trusts annual ETC threshold. Such costs can sometimes be identified by the Research Delivery Facilitators as they review study paperwork. Any research studies where such costs are identified will not be supported by R&D, they will only be opened if a Care Group agrees in writing to cover them themselves.

4. Our processes

Every quarter the Research Delivery Facilitators will input the number of patients recruited into a study, with identified ETCs in them (taken from the R&D IT system EDGE) into the ETC tracker spreadsheet. Every Quarter this will be checked against the ETC report that the Clinical Research Network (CRN) send to the Head of R&D and the Deputy Finance Manager, as well as pulling a report from ODP?

If the Trust reaches the Trusts ETC threshold in a financial year, the Deputy Finance Manager instructs the CRN (giving details of our expenditure via the ETC tracker). The Trust will then start to get the automatic ETC payments to cover the rest of the ETCs in that financial year from the CRN, payments are received quarterly.

R&D's Deputy Finance Manager will arrange for an internal transfer to cover ETC's to the Care Group incurring them every quarter.

5. Conclusion

This paper sets out to introduce a model for the funding of ETCs that is relatively easy to apply,

This guidance has been approved by Andy Bertram, Director of Finance for a 1st April 2023 implementation and will be kept under review.